Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.
We add new providers as they enter the market and update existing scores as providers change their policies, pricing, or clinical offerings
Signs of Hyperglycemia or Treatment Failure Excessive urination accompanied by increased thirst (polydipsia), unexplained fatigue, blurred vision, or unintentional weight loss may indicate inadequate glycemic control
Tissue and species differences in enzymes of epoxide metabolism
APPENDIX: GLP-1 and Addiction Human Trials in Progress Please be in touch if you are aware of other trials that are not listed below